The potential use of selective 5-HT2C agonists in treating obesity

@article{Smith2006ThePU,
  title={The potential use of selective 5-HT2C agonists in treating obesity},
  author={Brian M. Smith and William J. Thomsen and Andrew J Grottick},
  journal={Expert Opinion on Investigational Drugs},
  year={2006},
  volume={15},
  pages={257 - 266}
}
Activation of central 5-HT2C receptors as a strategy for appetite suppression and weight control is supported by animal pharmacology and human clinical studies. Considerable evidence comes from the weight-loss effects of fenfluramine, a non-selective 5-HT2C agonist. Advances in molecular pharmacology have led to an understanding of the effects of 5-HT2C receptor activation on food intake and satiety, in addition to providing insight into the causes of cardiac valvular insufficiency and… 
Pharmacological targeting of the serotonergic system for the treatment of obesity
TLDR
Serotonergic compounds reducing ingestive behaviour are reviewed and their clinical potential for the treatment of obesity is discussed.
Anti-obesity pharmacotherapy: Future perspectives utilising 5-HT2C receptor agonists
TLDR
There remains considerable optimism that 5-HT2C receptor agonists will add to the pharmacological arsenal to fight obesity.
Targeting 5-HT receptors for the treatment of obesity.
TLDR
5-HT(6) receptor antagonists appear to offer great promise, although the mechanisms through which they reduce food intake and body weight are not fully understood.
Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.
TLDR
The synthesis and structure-activity relationships of a series of novel tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists are presented and several members of this series were identified as potent 5- HT2C receptors agonists with high functional selectivity against the 5.HT2A and 5-ht2B receptors and reduced food intake in an acute rat feeding model upon oral dosing.
Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel?
TLDR
The success of future 5-HT(₂C) agonists will depend on further improvements in selectivity (or attainment of complete specificity) and pharmaceutical properties to permit greater and sustained receptor stimulation, while avoiding side effects associated with the activation of other 5- HT receptors.
Centrally Acting Anti-Obesity Agents
TLDR
This chapter discusses agents that target central pathways involved in controlling food intake, body weight, and reward and that are under active investigation.
Appetite suppressants, cardiac valve disease and combination pharmacotherapy.
TLDR
The evidence that cardiac valve disease involves activation of mitogenic serotonin 2B (5-HT2B) receptors by norfenfluramine, the major metabolite of fenfluramines, is discussed.
Identification of Novel 1-O-substituted Aporphine Analogues as Potent 5-HT2C Receptor Agonists.
TLDR
The findings may serve as good starting points for the development of more potent and selective 5-HT2C agonists as valuable pharmacological tools or potential drug candidates.
Lorcaserin: an investigational serotonin 2C agonist for weight loss.
  • Kathryn M. Hurren, H. Berlie
  • Medicine
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2011
TLDR
Lorcaserin, a 5-HT(2C) agonist, has demonstrated efficacy in patients who are obese or are overweight with associated comorbidities, and Phase III trials have found that more than 35% of patients lost greater than 5% of their baseline weight.
Serotonergic drugs and valvular heart disease
TLDR
A more likely cause of fenfluramines-induced valvulopathy is activation of 5-HT2B receptors on heart valves by the metabolite norfenfluramine, and future serotonergic medications should be designed to lack 5- HT2B agonist activity.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 76 REFERENCES
Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity.
  • K. Miller
  • Medicine
    Molecular interventions
  • 2005
TLDR
Development of highly selective 5-HT(2C) agonists may recapitulate the clinical anti-obesity properties observed with fenfluramine while avoiding the significant cardiovascular and pulmonary side effects.
5-HT2C receptor agonists as potential drugs for the treatment of obesity.
  • M. Bickerdike
  • Biology, Medicine
    Current topics in medicinal chemistry
  • 2003
TLDR
Both the pre-clinical and clinical evidence supporting the use of 5-HT(2C) receptor agonists for the treatment of obesity is reviewed and the developments that have been made to date are assessed.
New 5-HT2C receptor agonists
TLDR
This review will focus on recent patent applications through August 2003 that describe compounds that have agonist activity at the 5-HT2C receptor, and should be complementary to previous Expert Opinion discussions on the5-HT1C receptor.
Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity.
The pivotal role of 5-HT in the control of appetite was formally proposed nearly 30 years ago. In particular endogenous hypothalamic 5-HT has been implicated in the processes of within meal satiation
5-HT2C receptor activation decreases appetite and body weight in obese subjects
TLDR
It is suggested that during 2 weeks treatment in humans, mCPP may continue to activate brain 5-HT2C receptors, and that this effect is associated with decreases in appetite and body weight.
5-HT 2C Receptor Agonists for the Treatment of Obesity. Biological and Chemical Adventures
Obesity is a major risk factor in the development of conditions such as hypertension, hyperglycemia, dyslipidemia, coronary artery disease and cancer. There is increasing evidence suggesting an
Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.
TLDR
Several compounds are shown to be potent and selective 5-HT(2C) receptor agonists, which decrease food intake in a rat feeding model.
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension
TLDR
Using the chronic-hypoxic-mouse model of pulmonary hypertension, it is found that the hypoxia-dependent increase in pulmonary blood pressure and lung remodeling are associated with an increase in vascular proliferation, elastase activity and transforming growth factor-β levels, and that these parameters are potentiated by dexfenfluramine treatment.
The role of 5-HT2C receptors in affective disorders.
TLDR
Results are consistent with an important hypothesis proposing that 5-HT has a complex, dual action on the neural mechanism of anxiety by either facilitating or inhibiting different kinds of anxiety in different brain regions and suggest that5-HT(2C) receptor subtypes play an important role in the therapeutic properties of SSRIs.
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
TLDR
CB1 blockade with rimonabant 20 mg, combined with a hypocaloric diet over 1 year, promoted significant decrease of bodyweight and waist circumference, and improvement in cardiovascular risk factors.
...
1
2
3
4
5
...